Dordaviprone hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for dordaviprone hydrochloride and what is the scope of freedom to operate?
Dordaviprone hydrochloride
is the generic ingredient in one branded drug marketed by Chimerix and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dordaviprone hydrochloride has two hundred and seventy-seven patent family members in thirty countries.
One supplier is listed for this compound.
Summary for dordaviprone hydrochloride
| International Patents: | 277 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 13 |
| DailyMed Link: | dordaviprone hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dordaviprone hydrochloride
Generic Entry Date for dordaviprone hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for dordaviprone hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Nebraska | Phase 1 |
| Chimerix | Phase 1 |
US Patents and Regulatory Information for dordaviprone hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chimerix | MODEYSO | dordaviprone hydrochloride | CAPSULE;ORAL | 219876-001 | Aug 6, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chimerix | MODEYSO | dordaviprone hydrochloride | CAPSULE;ORAL | 219876-001 | Aug 6, 2025 | RX | Yes | Yes | 9,265,765 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Chimerix | MODEYSO | dordaviprone hydrochloride | CAPSULE;ORAL | 219876-001 | Aug 6, 2025 | RX | Yes | Yes | 11,976,068 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Chimerix | MODEYSO | dordaviprone hydrochloride | CAPSULE;ORAL | 219876-001 | Aug 6, 2025 | RX | Yes | Yes | RE46290 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chimerix | MODEYSO | dordaviprone hydrochloride | CAPSULE;ORAL | 219876-001 | Aug 6, 2025 | RX | Yes | Yes | 10,369,154 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chimerix | MODEYSO | dordaviprone hydrochloride | CAPSULE;ORAL | 219876-001 | Aug 6, 2025 | RX | Yes | Yes | 10,172,862 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for dordaviprone hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017132661 | ⤷ Start Trial | |
| China | 106163524 | ⤷ Start Trial | |
| Japan | 7579684 | ⤷ Start Trial | |
| Canada | 2930535 | ⤷ Start Trial | |
| Slovenia | 2701708 | ⤷ Start Trial | |
| Spain | 3009132 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
